Masculinizing Effects of Initiating Testosterone enanthate in combination with finasteride among transmasculine persons: A randomized double-blinded controlled study

Masculinizing Effects of Initiating Testosterone enanthate in combination with finasteride among transmasculine persons: A randomized double-blinded controlled st

Status

Recruiting

Phases

Phase 2

Study type

Interventional

Source

TCTR

Registry ID

TCTR20250709010

Enrollment

Registered

2025-07-09

Start date

2024-12-06

Completion date

Unknown

Last updated

2026-08-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Gender dysphoria Transgender men Androgenic side effects Androgenetic alopecia Acne Gender Dysphoria Transgender Persons Hormone Replacement Therapy Testosterone Finasteride Alopecia, Androgenetic Acne Vulgaris

Interventions

1. Testosterone enanthate intramuscular injection 100 mg every 2 weeks 2. Finasteride oral 1 mg daily for 48 weeks,1. Testosterone enanthate intramuscular injection, 100 mg every 2 weeks 2. Placebo or

Experimental Drug,Placebo Comparator Drug

Testosterone enanthate + Finasteride,Testosterone enanthate + Placebo

Eligibility

Sex/Gender

Female

Age

18 Years to 75 Years

Inclusion criteria

Inclusion criteria: 1. Transgender men 2. Receiving testosterone therapy for the first time 3. Age greater than or equal to 18 years 4. Able to comply with the follow-up schedule 5. Healthy with no major chronic illness 6. Provided written informed consent

Exclusion criteria

Exclusion criteria: 1. Immunodeficiency 2. Age more than 75 3. Active athletes engaging in weight training 4. Bleeding disorders or on anticoagulants 5. Pregnancy or breastfeeding 6. Psychiatric disorders including trichotillomania 7. Eating disorders or under dietary control 8. Scalp skin diseases (e.g., seborrheic dermatitis, psoriasis) Withdrawal of consent

Design outcomes

Primary

Measure	Time frame
Muscle mass Baseline, 6 months, 12 months InBody scan,body hair distribution Baseline, 6 months, 12 months Modified Ferriman-Gallwey scoring system	—

Secondary

Measure	Time frame
Scalp hair loss grade Baseline, 6, 12 months Hamilton-Norwood classification,Skin oiliness Baseline, 3, 6, 12 months Sebumeter,Sexual function Baseline, 12 months ASEX-Thai,Quality of life Baseline, 12 months WHOQOL-BREF-THAI,Patient satisfaction 12 months Visual analogue scale (10-point)	—

Countries

Thailand

Contacts

Public ContactTeerapong Rattananukrom

Faculty of Medicine, Ramathibodi Hospital, Mahidol University

teerpongrattananukrom@gmail.com0885953561

Outcome results

None listed

Source: TCTR (via WHO ICTRP) · Data processed: Aug 10, 2026